SEARCH

Current Edition

news

Novo Nordisk to boost drug manufacturing in Denmark

Danish drugmaker Novo Nordisk will spend 5.4 billion Danish kroner, or about $744 million, to expand its clinical manufacturing facilities in a suburb near Copenhagen, Denmark. …

Continue Reading →
news

FDA approves first gene therapy for hemophilia B

The Food and Drug Administration on Tuesday approved the first gene therapy for a type of hemophilia, giving people with the inherited disorder a treatment …

Continue Reading →
news

Teva taps Sandoz veteran to take over CEO post from Schultz

Generic drugmaker Teva Pharmaceutical on Monday named former Sandoz head Richard Francis as its next CEO, taking over on Jan. 1 from Kåre Schultz, who …

Continue Reading →
news

Merck to buy blood cancer biotech Imago for $1.35B

Merck & Co. has agreed to acquire Imago BioSciences, a California-based biotechnology company focused on bone marrow disorders, for more than $1 billion in cash. …

Continue Reading →
news

GSK to pull blood cancer drug from US market after study failure

GSK will pull a blood cancer drug from the U.S. market after the treatment failed in a confirmatory clinical trial, the British drugmaker announced Tuesday. …

Continue Reading →
news

Former Rubius CEO to lead buzzy Flagship startup

Just two days after stepping down from his last job, former Rubius Therapeutics head Pablo Cagnoni is again leading a biotech, joining another startup backed …

Continue Reading →
news

FDA panel votes in favor of Ardelyx’s once-rejected kidney disease drug

Dive Brief: A Food and Drug Administration advisory panel on Wednesday backed Ardelyx’s drug for kidney disease patients, lending weight to the company’s appeal of a …

Continue Reading →
news

Biotechs reveal layoffs, research revamps in third quarter earnings

Third quarter earning reports have brought news of layoffs from at least six biotechnology companies this week as a weak market continues to weigh on …

Continue Reading →
news

First-of-its-kind Type 1 diabetes drug wins FDA approval

Dive Brief: One year after an initial regulatory rejection, Provention Bio’s injectable drug teplizumab has won Food and Drug Administration approval for preventive treatment of …

Continue Reading →
news

Under FDA pressure, GSK limits use of ovarian cancer drug

GSK will stop selling the drug Zejula for some ovarian cancer patients whose disease is stable after a second line of chemotherapy, the company said …

Continue Reading →
news

FDA declines to review Brainstorm’s ALS therapy

Dive Brief: Brainstorm Cell Therapeutics said Thursday that the Food and Drug Administration has decided not to review an approval application for a cell therapy …

Continue Reading →
news

Biogen names former Sanofi head Viehbacher to replace Vounatsos as CEO

Biogen on Thursday named former Sanofi executive Christopher Viehbacher to replace Michel Vounatsos as its CEO, ending a six-month search for new leadership and putting …

Continue Reading →
news

Seagen picks Novartis, Flagship veteran Epstein as new CEO

Cancer drugmaker Seagen on Thursday appointed longtime Novartis executive David Epstein as its new CEO, ending a search that began when the company’s founder, Clay …

Continue Reading →
news

Early data hint at benefit for Amgen’s obesity drug

An experimental drug from Amgen helped people who are obese lose up to 15% of their body weight in a short study, a finding that …

Continue Reading →
news

CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Growth and Quality scores improved dramatically across all markets, with India the overall biggest winner Frankfurt/Amsterdam, 1st November 2022: Pharma confidence in growth, innovation and …

Continue Reading →
news

CPHI Excellence in Pharma Award Winners 2022

The CPHI Pharma Awards recognise progress and innovation  across the pharma supply chain. This year’s winners are:   CEO of the Year – Manni Kantipudi, …

Continue Reading →
news

Rubius replaces CEO as it cuts more jobs and considers a sale

Dive Brief: Four years after going public with a valuation of about $2 billion, Rubius Therapeutics has laid off almost all its employees and is …

Continue Reading →
news

String of gene therapy deals spurs cautious optimism on Wall Street

Despite safety concerns and pushback from drug regulators, gene therapy continues to be an area of interest to biopharmaceutical dealmakers, as shown by a recent …

Continue Reading →
news

Galapagos to cut 200 jobs amid research revamp

Belgian biotechnology company Galapagos plans to eliminate approximately 200 positions as part of a “new strategic direction” that narrows its research activities. Paul Stoffels, the former …

Continue Reading →
news

Bispecific cancer drugs and gene therapy advances: What to watch at next month’s ASH meeting

Next month, blood disease specialists and doctors will travel to New Orleans for the 64th annual meeting of the American Society of Hematology, a high-profile …

Continue Reading →